Meta menu:

From here, you can access the Emergencies page, Contact Us page, Accessibility Settings, Language Selection, and Search page.

  • Contact us:

    Humboldt Graduate SchoolCharitéplatz 1 (local address: Luisenstraße 56)
    10117 Berlin

  • Accessibility:
    Contrast Settings Change contrast
    Font size
    Font size bigger: STRG+ Font size smaller: STRG-

    You can enlarge or reduce the browser window. Please use CTRL and + to zoom in or CTRL and - to zoom out. Press CTRL and 0 to reset your browser window to normal size.

Open Menu

Scientific Workshop

You are here:

Scientific Workshop: Translational Research

Topic 1: In vivo assessment of potential therapeutic compounds and candidate selection

Bueters et al. Correct assessment of new compounds using in vivo screening models can reduce false positives. Drug Discov Today. 2009 Jan;14(1-2):89-94. doi: 10.1016/j.drudis.2008.09.003.

Visser et al. Model-based drug discovery: implementation and impact. Drug Discov Today. 2013 Aug;18(15-16):764-75. doi: 10.1016/j.drudis.2013.05.012.

van der Worp et al. Therapeutic hypothermia for acute ischemic stroke: ready to start large randomized trials? J Cereb Blood Flow Metab. 2010 Jun;30(6):1079-93. doi: 10.1038/jcbfm.2010.44.

Topic 2: Failure to translate

Savitz. A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. Exp Neurol. 2007 May;205(1):20-5. doi: 10.1016/j.expneurol.2007.03.003.

Feuerstein et al. Missing steps in the STAIR case: a Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke. J Cereb Blood Flow Metab. 2008 Jan;28(1):217-9. doi: 10.1038/sj.jcbfm.9600516.

Topic 3: Success to translate

Capdeville et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov. 2002 Jul;1(7):493-502. doi: 10.1038/nrd839.

Dell'Italia. Translational Success Stories: Angiotensin Receptor 1 Antagonists in Heart Failure. Circ Res. 2011;109:437-452. doi: 10.1161/CIRCRESAHA.110.238550.

Topic 4: Innovative clinical trials

Tunis et al. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003; 290:1624-1632.

Orloff et al. The future of drug development: advancing clinical trial design. Nat Rev Drug Discov. 2009 Dec;8(12):949-57. doi: 10.1038/nrd3025.

Orloff, Stanski. Innovative approaches to clinical development and trial design. Ann Ist Super Sanita. 2011;47(1):8-13. doi: 10.4415/ANN_11_01_03.

Topic 5: Reverse Translation

Moore. Reverse translation: clearing a path from bedside to bench. Nature. 2008 Jul 17;454(7202):274. doi: 10.1038/454274a.

Ledford. Translational Research: The full cycle. Nature. 2008 June; 453(843-845). doi: 10.1038/453843.

Topic 6: Drug selectivity in psychiatry

Newman-Tancredi, Kleven. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology (Berl). 2011 Aug;216(4):451-73. doi: 10.1007/s00213-011-2247-y.

Roth et al. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov. 2004 Apr;3(4):353-9. PMID: 15060530.

Kenakin, Christopoulos. Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov. 2013 Mar;12(3):205-16. doi: 10.1038/nrd3954.

Outline of the Meeting

July 10 - 15, 2014, Berlin

Program, Day:
1: Theses Presentations
2: Program Evaluations
3: Social
4: Workshops
5: Lectures
6: Scientific Workshops

" full program


Program booklet

Program at a glance